Newsletter Tool

Today’s Big News

Mar 13, 2025

‘I don't feel we lost momentum’: Takeda’s oncology execs sharpen focus after restructuring

NIH allegedly cancels dozens of grants for vaccine hesitancy research: reports

Hologen AI commits up to $430M to help take MeiraGTx’s Parkinson’s gene therapy through phase 3 and beyond

Sotio takes up option on ADCs, while Boehringer inks GPCR discovery pact

ImmunoPrecise teases $10M ADC, bispecific collab with major biotech

Trump administration withdraws Dave Weldon CDC nomination

Moderna CEO Stéphane Bancel scored pay bump in 2024 despite revenue decline and missed sales target

Featured

‘I don't feel we lost momentum’: Takeda’s oncology execs sharpen focus after restructuring

By Gabrielle Masson

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the company’s focus on cell therapy to the backburner.

NIH allegedly cancels dozens of grants for vaccine hesitancy research: reports

By Darren Incorvaia

The National Institutes of Health (NIH) is reportedly continuing its grant-canceling spree, now targeting dozens of research projects related to studying vaccine hesitancy and improving vaccine rates.

Hologen AI commits up to $430M to help take MeiraGTx’s Parkinson’s gene therapy through phase 3 and beyond

By James Waldron

Artificial intelligence company Hologen AI has committed up to $430 million as part of a multi-faceted agreement to help take MeiraGTx’s Parkinson’s disease gene therapy all the way to market.

Sotio takes up option on ADCs, while Boehringer inks GPCR discovery pact

By Nick Paul Taylor

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates, taking up its option to use Synaffix’s technology in two candidates. The Czech biotech disclosed the update on the same day as Salipro Biotech revealed a partnership with Boehringer Ingelheim.

ImmunoPrecise teases $10M ADC, bispecific collab with major biotech

By James Waldron

ImmunoPrecise Antibodies has secured a collaboration with an undisclosed “leading biotech” to discover new antibody-drug conjugates (ADCs) and bispecific antibodies to treat cancer.

Trump administration withdraws Dave Weldon CDC nomination

By Heather Landi

The Trump administration withdrew its nominee to run the Centers for Disease Control and Prevention just hours before his Senate confirmation hearing, multiple media outlets reported Thursday.

Moderna CEO Stéphane Bancel scored pay bump in 2024 despite revenue decline and missed sales target

By Zoey Becker

While Stéphane Bancel received a lower-than-targeted bonus on the back of declining revenue and a missed sales goal, his total pay was still a record high.

Clario acquires WCG's neuroscience-focused clinical outcome assessment business

By Darren Incorvaia

Tech firm Clario is boosting its electronic clinical outcome assessment (eCOA) offerings by acquiring the neuroscience-focused eCOA business of WCG.

J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms

By Angus Liu

On track to meet their long-stated capacity goal for multiple myeloma therapy Carvykti in 2025, Johnson & Johnson and Legend Biotech are already planning the next phase of their cell therapy manufacturing expansion.

Eye surgery specialist BVI Medical claims $1B capital raise through owner TPG

By Conor Hale

BVI said the move fully refinances its debt and adds new equity, both from TPG and additional new investors.

Fierce podcasts

Don’t miss an episode

Ways providers can simplify patient billing

Some health tech companies help providers communicate more proactively with patients about what they might owe and what repayment options are available to them.

A look at biotech's biggest money raisers of 2024

What’s next for digital health investing in 2025?

Resources

Whitepaper

The Oncology Market: 2025 Outlook

Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Redefining vaccine trial recruitment

Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials.

Sponsored by: Avacare Clinical Research Network

Whitepaper